NDATOPICALOINTMENT
Approved
Aug 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
BETAMETHASONE VALERATE (betamethasone valerate) by Sandoz is clinical pharmacology: topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. First approved in 1983.
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Betamethasone valerate is a potent topical corticosteroid ointment used to treat inflammatory skin conditions by reducing inflammation, itching, and vasodilation. It works through mechanisms that inhibit inflammatory mediators and immune responses at the dermal level. The drug is absorbed through intact and inflamed skin and metabolized hepatically before renal excretion.
$4MPart D
LOE ApproachingProduct is in late-stage lifecycle with modest Part D spending, indicating small team size and focus on maintenance rather than growth.
Mechanism of Action
CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on BETAMETHASONE VALERATE at Sandoz? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.